Company news
3sbio, Inc. (HKEX:1530) news
3sbio, Inc. news releases on 6ix. Latest, Oct 2, 2026: Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Press releases & updates
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
October 2, 2026
2026 Interim Report
September 30, 2026
Next Day Disclosure Return
September 29, 2026
Next Day Disclosure Return
September 28, 2026
3SBio Announces 2025 Annual Results: Dual Engines of Innovative R&D and Global Collaboration Propel Revenue Past RMB 10 Billion Milestone
March 31, 2026
Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance
February 3, 2026
Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance
December 16, 2025
Pfizer Reports Solid Third-Quarter 2025 Results; Raises and Narrows 2025 EPS Guidance
November 4, 2025
3SBio : 2025 Interim Results Presentation
August 31, 2025
Pfizer Reports Strong Second-Quarter 2025 Results And Raises 2025 EPS Guidance
August 5, 2025
Pfizer Completes Licensing Agreement with 3SBio
July 24, 2025
3SBio : 2024 ESG Report
April 30, 2025
3SBio Unveils 2024 Annual Results: Profit Surges 34.9% YoY, Innovation Pipeline Delivers Strong Value
March 25, 2025
3SBio : 2025 43rd Annual J.P. Morgan Healthcare Conference Corporate Presentation
January 21, 2025
3SBio : 2024 Interim Report
September 30, 2024
3SBio Unveils 2024 Interim Results: Revenue Up 16% YoY, Autoimmune Pipeline Poised for a Promising Phase
August 21, 2024
3SBio announces 2023 interim results, with revenue growing over 20% year on year and pipeline value constantly enhanced
August 23, 2023
3SBio : 2022 ESG Report
April 28, 2023
3SBio announces 2022 annual results, with revenue rising 7.5% year on year and normalized net profit attributable to parents jumping 25.2%
March 20, 2023
3SBio : 2022 Interim Results Presentation
August 24, 2022
3SBio : 1530.HK) _ Prospectus
June 24, 2022
3SBio : 2021 ESG Report
May 24, 2022
3SBio : 2021Annual Report
April 29, 2022
3SBio : announces 2021 annual results, with net profit attributable to owns of the parents almost doubling under accelerated growth of diversified businesses
March 30, 2022
3SBIO : 2021Annual Results
March 28, 2022
3SBio : Documents on Display
December 21, 2021
3SBio : announces 2021 interim results, with strong growth in core businesses and significant progress in clinical development
August 26, 2021
3SBio : announces 2020 annual results, tapping integrated platform advantages for steady growth
March 30, 2021
3SBio Inc. : received milestone payment of USD 4 million upon commencement of phase III clinical program of SEL-212
November 23, 2020
3SBio : Announces Acceptance of IND application for bevacizumab biosimilar in China
September 14, 2020
3SBio : VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE IND APPLICATION FOR BEVACIZUMAB BIOSIMILAR IN MAINLAND CHINA
September 14, 2020